



(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
C07K 16/30 (2006.01)

(21) International Application Number:

PCT/US2022/032006

(22) International Filing Date:

02 June 2022 (02.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/197,265 04 June 2021 (04.06.2021) US
63/236,547 24 August 2021 (24.08.2021) US

(71) Applicants: **AMGEN RESEARCH (MUNICH) GMBH** [DE/DE]; Staffelseestrasse 2, 81477 Munich (DE). **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).


(72) Inventors: **BROZY, Johannes**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **DAHLHOFF, Christoph**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **RAUM, Tobias**; c/o Amgen Research (Munich) GmbH,

Staffelseestrasse 2, 81477 Munich (DE). **PENDZIALEK, Jochen, S.**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **WINKEL, Lisa**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **MUENZ, Markus**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **PIERCE, Nathan, William**; c/o Amgen Inc., Law Department-Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **KIELCZEWSKA, Agnieszka**; c/o Amgen Inc., Law Department-Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **CHEN, Wentao**; c/o Amgen Inc., Law Department-Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **BATES, Darren, L.**; c/o Amgen Inc., Law Department-Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **BLUEMEL, Claudia**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **HONER, Jonas, Karl-Josef**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE).

(74) Agent: **THOBE, Megan**; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(54) Title: T CELL ENGAGER MOLECULES AND USES THEREOF

FIG. 1



(57) Abstract: The present invention provides single chain T cell engager (TCE) molecules having an scFab that binds a target antigen and an scFv that binds CD3, and TCE molecules that bind CCR8 and CD3. Methods of treating cancer are also provided.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*